Has Sanjay Ahuja received payments from drug or device companies?

Yes. Drug and device makers reported $197,182 in general payments to Sanjay Ahuja across 308 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sanjay Ahuja did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sanjay Ahuja come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sanjay Ahuja

Pediatric Hematology-Oncology · Indianapolis, INNPI 1306820717

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $129,567 of the $197,182 with a category attached, or 65.7%. 46 manufacturers reported payments, led by Sanofi at 49.1% of the total. Among pediatric hematology-oncology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$197,182in general payments, 2019–2025

Across 308 payments — averaging $640.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$97K
Genentech USA, Inc.$25K
CSL Behring$15K
Bioverativ Therapeutics Inc.$15K
HEMA Biologics, LLC$12K
Novo Nordisk AS$10K
plus $23K from 40 others

$1,233,048in research payments, 2019–2025

Across 402 payments — averaging $3067.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novo Nordisk AS$330K
Sanofi$247K
Takeda Pharmaceuticals U.S.A., Inc.$185K
Pfizer$145K
Bayer$144K
Regeneron$41K
plus $141K from 7 others

What the payments were for

Consulting fees$129,56766%
Speaking & faculty fees$38,90920%
Travel & lodging$20,87011%
Food & beverage$7,7324%
Education$1040%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	60	$96,772
Genentech USA, Inc.	41	$25,417
CSL Behring	31	$15,311
Bioverativ Therapeutics Inc.	25	$14,636
HEMA Biologics, LLC	19	$12,318
Novo Nordisk AS	4	$9,549
Sanofi US Services Inc.	1	$8,201
Biomarin Pharmaceutical Inc.	5	$5,489
Novo Nordisk	9	$3,094
Swedish Orphan Biovitrum AB	1	$2,177
Pfizer	5	$1,542
Genentech, Inc.	3	$616
Novartis	13	$260
AstraZeneca(2 entities)	12	$206
Amgen	10	$199
Takeda Pharmaceuticals U.S.A., Inc.	7	$155
AVEO Pharmaceuticals, Inc.	7	$138
Bayer	6	$130
Shire North American Group Inc	4	$127
Eisai Inc.	5	$101
Incyte Corporation	4	$79
Jazz Pharmaceuticals Inc.	4	$77
Astellas Pharma US Inc	3	$65
Beigene USA, Inc.	2	$42
Genmab U.S., Inc.	2	$41
Pharmacyclics LLC, An Abbvie Company	2	$39
Ipsen Biopharmaceuticals, Inc	2	$38
Global Blood Therapeutics, Inc.	2	$35
Seagen Inc.	2	$29
Acrotech Biopharma Inc.	1	$24
Helsinn Therapeutics (U.S.), Inc.	1	$23
Sobi, Inc	1	$22
Karyopharm Therapeutics Inc.	1	$22
Bristol Myers Squibb	1	$21
Blueprint Medicines Corporation	1	$21
GSK	1	$20
Puma Biotechnology, Inc.	1	$19
Aurobindo Pharma USA, Inc.	1	$18
EMD Serono, Inc.	1	$16
E.r. Squibb & Sons, L.L.C.	1	$16
Apo-pharma USA, Inc.	1	$16
Chiesi USA, Inc.	1	$15
Grifols USA, LLC	1	$14
Dova Pharmaceuticals	1	$13
Teva Pharmaceuticals USA, Inc.	1	$11
Emmaus Medical, Inc.	1	$6

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

HEMLIBRA$18,924
SevenFact$11,588
REBINYN$11,079
ALTUVIIIO$8,896
HEMGENIX$6,525
FITUSIRAN$6,398
Roctavian$5,471
Non-Covered Product$4,000
ELITEK$3,668
ALPROLIX$2,275
Idelvion$1,680
NovoSeven RT$1,360
ELOCTATE$1,359

How this compares

$197,182 in reported general payments places this provider in the 95th percentile of 59 pediatric hematology-oncology providers in Indiana.

See all pediatric hematology-oncology providers in Indiana →

Other pediatric hematology-oncology in Indianapolis

Amy ShapiroIndianapolis$287K
Bassem RazzoukIndianapolis$42K
Melissa BearIndianapolis$26K
Steven RhodesIndianapolis$13K
Kyle DavisIndianapolis$10K
Seethal JacobIndianapolis$8K
Charles NakarIndianapolis$5K
Scott CovenIndianapolis$4K
Sandeep BatraIndianapolis$4K
Kerry HegeIndianapolis$3K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →